Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Apple
AAPL
|
+$763M |
| 2 |
Amazon
AMZN
|
+$688M |
| 3 |
TSMC
TSM
|
+$562M |
| 4 |
Tesla
TSLA
|
+$419M |
| 5 |
Johnson & Johnson
JNJ
|
+$398M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
Novo Nordisk
NVO
|
+$366M |
| 4 |
JPMorgan Chase
JPM
|
+$335M |
| 5 |
ASML
ASML
|
+$325M |
Sector Composition
| 1 | Healthcare | 20.8% |
| 2 | Technology | 15.52% |
| 3 | Consumer Discretionary | 11.85% |
| 4 | Consumer Staples | 10.11% |
| 5 | Financials | 9.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BIOL
3901
DELISTED
Biolase, Inc.
BIOL
| $28K | ﹤0.01% |
431
+243
| +129% | +$15.8K |
|
|
MCOM
3902
DELISTED
micromobility.com Inc. Class A Common stock
MCOM
| $28K | ﹤0.01% |
+28
| New | +$28K |
|
3903
Aethlon Medical
AEMD
$1.93M
| $28K | ﹤0.01% |
1,258
+479
| +61% | +$10.7K |
|
3904
Alzamend Neuro
ALZN
$7.5M
| $28K | ﹤0.01% |
+37
| New | +$28K |
|
3905
CLPS Inc
CLPS
$29.4M
| $28K | ﹤0.01% |
24,932
+11,100
| +80% | +$12.5K |
|
|
AUUD
3906
Auddia
AUUD
$4.7M
| $27K | ﹤0.01% |
67
-56
| -46% | -$22.6K |
|
3907
Twin Vee PowerCats
VEEE
$5.82M
| $27K | ﹤0.01% |
+1,450
| New | +$27K |
|
3908
VivoPower
VVPR
$52.1M
| $27K | ﹤0.01% |
11,040
+3,234
| +41% | +$7.91K |
|
|
NYMX
3909
DELISTED
Nymox Pharmaceutical Corp
NYMX
| $27K | ﹤0.01% |
+82,800
| New | +$27K |
|
|
SECO
3910
DELISTED
Secoo Holding Limited ADR
SECO
| $27K | ﹤0.01% |
14,590
| – | – |
|
3911
Allied Gaming & Entertainment
AGAE
$34.6M
| $26K | ﹤0.01% |
25,100
+2,100
| +9% | +$2.18K |
|
|
AKTX
3912
Akari Therapeutics
AKTX
$25.2M
| $26K | ﹤0.01% |
2,773
+770
| +38% | +$7.22K |
|
|
BQ
3913
Boqii Holding Limited
BQ
$10.3M
| $26K | ﹤0.01% |
651
-3
| -0.5% | -$120 |
|
3914
Inhibikase Therapeutics
IKT
$121M
| $26K | ﹤0.01% |
8,667
-12,114
| -58% | -$36.3K |
|
|
JFU
3915
9F Inc
JFU
$30.1M
| $26K | ﹤0.01% |
7,286
+6,350
| +678% | +$22.7K |
|
3916
NLS Pharmaceutics
NLSP
$10.1M
| $26K | ﹤0.01% |
505
-140
| -22% | -$7.21K |
|
|
KBNT
3917
DELISTED
Kubient, Inc. Common Stock
KBNT
| $26K | ﹤0.01% |
40,496
-1,700
| -4% | -$1.09K |
|
|
APPH
3918
DELISTED
AppHarvest, Inc. Common Stock
APPH
| $26K | ﹤0.01% |
+46,100
| New | +$26K |
|
3919
Bluejay Diagnostics
BJDX
$2.18M
| $25K | ﹤0.01% |
8
+2
| +33% | +$6.25K |
|
|
DUO
3920
Fangdd Network Group
DUO
$13.2M
| $25K | ﹤0.01% |
136
+27
| +25% | +$4.96K |
|
3921
Greenlane Holdings
GNLN
$4.64M
| $25K | ﹤0.01% |
+1
| New | +$25K |
|
|
LGMK
3922
DELISTED
LogicMark
LGMK
| $25K | ﹤0.01% |
114
-35
| -23% | -$7.68K |
|
3923
Myomo
MYO
$34.8M
| $25K | ﹤0.01% |
48,000
+7,200
| +18% | +$3.75K |
|
3924
NexGel
NXGL
$20.3M
| $25K | ﹤0.01% |
19,731
-1,100
| -5% | -$1.39K |
|
3925
Onconetix
ONCO
$4.76M
| $25K | ﹤0.01% |
7
-19
| -73% | -$67.9K |
|